GENE ONLINE|News &
Opinion
Blog

2018-09-26| Trials & Approvals

Innovent reports clinical trial results of its anti-PD-1 monoclonal antibody

by Rajaneesh K. Gopinath
Share To

Sintilimab, the first drug submitted for New Drug Application (NDA) by Innovent Biologics is making quick strides as a first-line of treatment for patients with non-squamous non-small cell lung cancer.

Sintilimab is a fully human IgG4 anti-PD-1 monoclonal antibody generated from yeast display technology. It binds to the programmed cell death 1 (PD-1) receptor on T cells thereby blocking the interaction of PD-L1 ligand and PD-1. This helps restore the T-cell immune response which destroys tumor cells. Developed in collaboration with Eli Lilly, Sintilimab has been received by over 400 human subjects in clinical studies for both solid and blood-borne cancers for safety and efficacy evaluation (1).

At the 21st Annual Meeting of Chinese Society of Clinical Oncology (CSCO) organized in Xiamen last week, Innovent Biologics Inc. presented the Phase Ib trial data from its neuroendocrine tumor (NET) and non-small cell lung cancer (NSCLC) cohorts. Dubbed as one of the largest clinical studies of anti-PD-1 antibody for the treatment of NET, the objective response rate (ORR) was found to be 22.7%, based on the data from 22 patients with at least one radiological assessment. Furthermore, in 19 patients with poorly differentiated neuroendocrine carcinoma, the ORR was 26.3%. As per the calculations made until the cutoff date on June 28, 2018, the median duration of response (DOR) was found to be 5.8 months, while the progression free survival (PFS) was 2.2 months. The median overall survival had not been reached and the drug safety profile was consistent with that of trials involving other tumors (2).

Earlier this year, Innovent published the preliminary result of its multicenter, single-arm, phase 2 registrational study (ORIENT-1 trial) of Sintilimab studied in patients with relapsed/refractory classical Hodgkin Lymphoma. The updated and final analysis were presented at the 2018 ASCO Annual Meeting in Chicago last June (3). More recently, the company also announced that the first patient has been dosed in a phase III clinical trial (ORIENT-11) studying the drug as a first-line of treatment for patients with non-squamous non-small cell lung cancer (NSCLC) (4).

References

  1. https://academic.oup.com/abt/article/1/2/45/5090099
  2. http://innoventbio.com/en/#/news/110
  3. http://innoventbio.com/en/#/news/102
  4. http://innoventbio.com/en/#/news/107

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Singapore’s A*STAR Invests in HoneyBear, Accelerating ARC Cancer Drug Development
2025-03-28
Once-in-a-Lifetime Hope as Personalized Vaccine Eradicates Advanced Kidney Cancer
2025-03-03
Lilly’s Omvoh’s Two-Year Journey Confirms Lasting Impact on Crohn’s Disease Treatment
2025-02-08
LATEST
Comparative Analysis of Tirzepatide (Zepbound/Mounjaro) and Semaglutide (Wegovy) for Weight Loss
2025-05-12
Donald Trump’s “Most Favored Nation” Executive Order on Drug Pricing
2025-05-12
Discover Investment Opportunities & Innovation at International Healthcare Week in Hong Kong from May
2025-05-12
The Buffett Paradox: Cola, Happiness, and a Biotech Longevity Enigma
2025-05-11
President to Sign Executive Order on Trade Enforcement Monday Morning
2025-05-11
Trump to Sign Executive Order Linking U.S. Drug Prices to International Levels.
2025-05-11
Podcast Highlights Agile Biopharmaceutical Firms’ Strategies for Navigating Complex Clinical Trials
2025-05-11
EVENT
2025-05-13
ASGCT 28th Annual Meeting 2025
New Orleans, U.S.A.
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
2025-06-16
US BIO International Convention
Boston, U.S.A.
Scroll to Top